Fibrogen Inc   (FGEN)

News about Fibrogen Inc

FibroGen Collaborates with Regeneron Pharmaceuticals to Advance Immuno-Oncology Treatment for Solid Tumors
Jun 03 2024
SAN FRANCISCO, June 03, 2024 - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company, has announced a clinical trial supply agreement wit...

*SAN FRANCISCO, May 23, 2024* - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company committed to pioneering therapeutic advancements for serious unmet medical needs, is celebrating a significant milestone with the announcement of positive interim data from the dose escalation portion of the Phase 1b/2 study of FG-3246 (FOR46). This study is conducted by the Universit...
May 23 2024
*FibroGen Showcases Clinical Breakthroughs in Cancer Therapy at ASCO 2024 and Upcoming KOL Investor Event**SAN FRANCISCO, May 23, 2024* - FibroGen, In...

Promising Results of FG-3246 in Phase 1 Monotherapy Study for Metastatic Castration-Resistant Prostate Cancer
Apr 02 2024
This article provides an overview of the topline results from the Phase 1 study conducted by FibroGen, Inc. and sponsored by Fortis Therapeutics. The...

FibroGen Assumes Full Control of Revolutionary Anemia Drug, Roxadustat, Except in China and South Korea; Retention of China Agreement Highlights Continued Focus on Expanding Reach in Largest CKD Market
Feb 26 2024
FibroGen, a leading biopharmaceutical company, has recently announced that it has regained all rights to its innovative therapeutic drug, Roxadustat, ...

FibroGen*s Pamrevlumab Shows Promise in Pancreatic Cancer Clinical Program
Feb 05 2024
FibroGen, Inc. (NASDAQ: FGEN) has recently announced its plans to host Part I of a virtual KOL (Key Opinion Leader) investor event series on February ...

Fibrogen Inc Witnesses Notable 155.062% Surge in Revenue Over Three-Month Fiscal Period Ending Sep 30, 2023
Nov 07 2023
Fibrogen Inc, a biotech company operating in a seasonal nature of business, has recently reported some positive changes in its financial per...

Failed to break-even despite of surge in revenue, in the financial second quarter of 2023
Aug 08 2023
Fibrogen Inc, a major player in the pharmaceutical preparations industry, has reported its financial results for the second quarter of 2023. Despite a...

Fibrogen Inc*s Financial Woes Deepen: Innovation Takes a Hit in Recent Fiscal Period
May 09 2023
Fibrogen Inc is a pharmaceutical and biotechnology company that specializes in the development of innovative therapies for the treatment of serious an...

In spite of the boost in revenue Profitability not Reached by the company amid the most recent fiscal period
Aug 10 2022

Redemption of Losses at the Major Pharmaceutical Preparations company all along the financial fourth quarter of 2022
Aug 10 2022

Critical times for in the third quarter of 2022 earnings season
Aug 10 2022

Fading Deficit at the Fibrogen Inc amid the first quarter of 2022
Aug 10 2022

The Major Pharmaceutical Preparations company has Turned into Profitability at FGEN in the financial span ending September 30 2021
Aug 10 2022


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com